It's entirely possible that Pfizer stock will indeed rebound this year. Perhaps the most likely reason for a bounce is the potential for positive clinical results that excite investors. Many will ...

Pfizer faces another year of revenue decline in 2026, as Covid and loss-of-exclusivity headwinds weigh on top line growth, despite management's guidance and cost-cutting efforts. Recurring unusual ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: A Pfizer logo is displayed at a research facility in the La Jolla neighborhood of San Diego, California, U.S., ...

A patient in an open label extension study of Pfizer’s hemophilia treatment Hympavzi has died, the company and several hemophilia advocacy groups confirmed this week. Pfizer is now working with its ...

SHANGHAI, CHINA - 2025/11/08: The Pfizer logo is presented at the 8th China International Import Expo. (Photo by Sheldon Cooper/SOPA Images/LightRocket via Getty Images) Pfizer (PFE) is encountering ...

Pfizer said revenue should come in at the lower end of its guidance for this year, while it expects less revenue in 2026 than in 2025, as the drugmaker’s efforts to remake its business continue to ...

Pfizer Inc. (NYSE: PFE) on Tuesday gave a first glimpse of its fiscal 2026 guidance. The U.S. pharma giant sees 2026 adjusted earnings of $2.80-$3.00 per share compared to the consensus of $3.06.

The therapy YP05002 is part of the GLP-1 agonist class of drugs and is currently in early-stage development. Sign up here. Under the terms of the agreement, YaoPharma will complete the ongoing ...

Elizabeth Holmes, serving a lengthy prison sentence for fraud, said Tuesday on social media that one of the most-damaging pieces of evidence against her — that she appropriated drug-companies’ logos ...

Pfizer’s mRNA flu vaccine outperformed the standard flu shot in a Phase 3 clinical trial, according to results published Wednesday in the New England Journal of Medicine. The vaccine uses the same ...

Signed, sealed and delivered, Metsera is finally Pfizer’s. Pfizer has completed its acquisition of the obesity biotech, capping a whirlwind two weeks in which rival pharma Novo Nordisk attempted to ...